Multidrug-resistant tuberculosis
diseaseOn this page
Also known as MDR-TBmultidrug-resistant TB
Summary
Multidrug-resistant tuberculosis (MONDO:0005861) is a disease and 31 clinical trials. Top therapeutic interventions include bedaquiline, delamanid, and clofazimine. A subtype of drug-resistant tuberculosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 31
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | multidrug-resistant tuberculosis |
| Mondo ID | MONDO:0005861 |
| EFO | EFO:0007381 |
| MeSH | D018088 |
| DOID | DOID:401 |
| NCIT | C128415 |
| SNOMED CT | 423092005 |
| UMLS | C0206526 |
| MedGen | 60163 |
| GARD | 0024245 |
| Is cancer (heuristic) | no |
Also known as: MDR-TB · multidrug-resistant TB
Disease family
This is a subtype of drug-resistant tuberculosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › tuberculosis › drug-resistant tuberculosis › multidrug-resistant tuberculosis
Related subtypes (3): rifampicin-resistant tuberculosis, extensively drug-resistant tuberculosis, totally drug-resistant tuberculosis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
2 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Delamanid | Approved (phase 4) |
| Pretomanid | Approved (phase 4) |
| Bedaquiline | Phase 3 (in late-stage trials) |
| Pyrazinamide | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Clofazimine, Ethionamide, Isoniazid, Kanamycin, Linezolid, Metronidazole, Moxifloxacin.
Clinical trials & evidence
Clinical trials
Clinical trials: 31.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 13 |
| PHASE3 | 6 |
| PHASE4 | 5 |
| PHASE2 | 4 |
| PHASE2/PHASE3 | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05493267 | PHASE4 | RECRUITING | A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB |
| NCT01521364 | PHASE4 | COMPLETED | Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients |
| NCT03867136 | PHASE4 | COMPLETED | Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T) |
| NCT04421495 | PHASE4 | UNKNOWN | Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China |
| NCT05278988 | PHASE4 | COMPLETED | A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB |
| NCT04260477 | PHASE3 | RECRUITING | Novel Triple-dose Tuberculosis Retreatment Regimen |
| NCT05081401 | PHASE3 | RECRUITING | Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB) |
| NCT07486024 | PHASE3 | NOT_YET_RECRUITING | Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR) |
| NCT01424670 | PHASE3 | COMPLETED | Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis |
| NCT02120638 | PHASE3 | UNKNOWN | Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide |
| NCT02409290 | PHASE3 | COMPLETED | The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB |
| NCT02454205 | PHASE2/PHASE3 | COMPLETED | An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis |
| NCT03069534 | PHASE2/PHASE3 | UNKNOWN | Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB |
| NCT05534750 | PHASE2 | RECRUITING | Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB) |
| NCT07393438 | PHASE2 | NOT_YET_RECRUITING | Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) |
| NCT00727844 | PHASE2 | COMPLETED | Linezolid to Treat Extensively-Drug Resistant Tuberculosis |
| NCT01859923 | PHASE2 | COMPLETED | A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB) |
| NCT01856634 | PHASE1 | COMPLETED | Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis |
| NCT02129244 | Not specified | ACTIVE_NOT_RECRUITING | A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes |
| NCT02496572 | Not specified | UNKNOWN | Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan |
| NCT02727582 | Not specified | COMPLETED | Pharmacometric Optimization of Second Line Drugs for MDR Tuberculosis Treatment |
| NCT02758236 | Not specified | COMPLETED | Tuberculosis Research of INA-RESPOND On Drug Resistance |
| NCT02984579 | Not specified | COMPLETED | Line Probe Assay Evaluation Study |
| NCT03604848 | Not specified | UNKNOWN | NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB |
| NCT03942354 | Not specified | COMPLETED | Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial |
| NCT04124055 | Not specified | COMPLETED | Saliva and Dried Blood Spot Therapeutic Drug Monitoring for MDR-TB in Tanzania |
| NCT04484129 | Not specified | UNKNOWN | MDR-TB Close Contacts Tracing in China (TCCT Study) |
| NCT04717908 | Not specified | COMPLETED | Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS |
| NCT05017324 | Not specified | UNKNOWN | Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial |
| NCT05175794 | Not specified | COMPLETED | Triage Test for All Oral DR-TB Regimen (TRiAD Study) |
| NCT06671808 | Not specified | COMPLETED | HIV and Multi-Drug Resistant Tuberculosis: a Study on Clinical Outcomes |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BEDAQUILINE | 4 | 5 |
| DELAMANID | 4 | 4 |
| CLOFAZIMINE | 4 | 3 |
| MOXIFLOXACIN | 4 | 3 |
| PYRAZINAMIDE | 4 | 3 |
| ISONIAZID | 4 | 2 |
| KANAMYCIN | 4 | 2 |
| ACETOHYDROXAMIC ACID | 4 | 1 |
| ETHAMBUTOL | 4 | 1 |
| ETHIONAMIDE | 4 | 1 |
| LINEZOLID | 4 | 1 |
| PRETOMANID | 4 | 1 |
| BEKANAMYCIN | 3 | 2 |
| PROTIONAMIDE | 3 | 1 |
| TERIZIDONE | 2 | 1 |
| CHEMBL5285059 | 0 | 4 |
| CHEMBL4761573 | 0 | 1 |
| CHEMBL4746300 | 0 | 1 |